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SARS-CoV-2 infection in a patient 
with propionic acidemia
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Abstract 
We describe a 14-month-old boy, with a previous diagnosis of propionic acidemia (PA) by expanded newborn screen-
ing, who, admitted for a suspected metabolic crisis, tested positive for SARS-CoV-2. Since propionic acidemia was 
diagnosed, the patient has followed the recommended diet for this inborn error of metabolism. Although propi-
onic acidemia patients are at a high risk of suffering metabolic crises, frequently associated with permanent clinical 
complications, psychomotor development of this patient was normal. The SARS-CoV-2 infection (at about 1 year of 
age) caused the patient’s first metabolic crisis. However, his clinical course was in keeping with a mild clinical form of 
COVID-19, and he recovered without experiencing severe clinical consequences. We describe this patient in order to 
improve the knowledge about follow up of PA patients identified by newborn screening and to increase the limited 
number of reports of SARS-CoV-2 infection in children with comorbidities, especially inborn errors of metabolism.
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Background
Propionic acidemia (PA) (MIM #606054) is a multisys-
temic inborn error of the catabolic pathway of branched-
chain amino acids (isoleucine, valine, methionine and 
threonine). It is caused by mutations in the PCCA and 
PCCB genes, encoding alpha and beta subunits (Uni-
ProtKB—P05165 and P05166) of the mitochondrial 
enzyme propionyl-CoA carboxylase (PCC, EC 6.4.1.3) 
[1]. Biochemical characteristics include metabolic acido-
sis, ketosis, hyperammonaemia, altered glycemia, neutro-
penia, anemia and thrombocytopenia [1].
PA is characterised by high levels of 3-hydroxypro-
pionate, methylcitrate, tiglylglycine and propionylgly-
cine in urine [2]. In recent years, an increasing number 
of patients have been detected by newborn screening 
(NBS) programs which check for elevated levels of C3 
(propionyl carnitine) in dried blood spots (DBS) taken 
from 48 to 72 h after birth [3].
The altered catabolism of proteins in PA causes severe 
psychomotor impairment, seizures, movement disor-
ders, gastrointestinal symptoms, cardiomyopathy, renal 
involvement, hematological abnormalities, osteoporo-
sis, immune dysfunctions and other symptoms. Most 
affected patients present the severe neonatal form, 
although later onset and milder forms are described [4].
An acute metabolic decompensation, which can result 
in selective organ damage, especially brain injury, can be 
avoided with therapy [1] and controlled diet [5]. In man-
aging PA patients, the key objective is to prevent acute 
episodes [5]. Acute decompensations, whose initial man-
agement is critical, can be triggered by fever, vomiting, 
prolonged fasting, gastroenteritis and other infections [5, 
6]. The health gains of NBS for PA in overall outcome are 
modest, even if mortality in patients detected by NBS is 
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The recent epidemic of the 2019 novel coronavirus 
SARS-CoV-2, has caused significant morbidity and mor-
tality worldwide. In general, children appear to have a 
milder clinical course compared to adults [8–11]. Little 
is known about SARS-CoV-2 infection in children with 
comorbidities (such as congenital heart, lung and airway 
diseases, chronic heart and kidney diseases, malnutrition, 
tumors, diabetes, immunodeficiency or hypoimmunity) 
and little information is available on the effects of the 
infection in pediatric patients with congenital inborn 
errors of metabolism (IEM) [8, 12]. However, emerg-
ing guidelines have been proposed to manage eventual 
SARS-Co V2 infection in lysosomal diseases and on 
inherited heart diseases [13–15]. In addition, it has been 
reported that a patient affected by mucolipidosis type II 
died because of pneumonia complicated by acute respira-
tory distress syndrome (ARDS) [16].
Here we describe a 14-month-old patient followed by 
our team since PA was detected by NBS and confirmed 
by PCCA and PCCB gene sequencing, who was recently 
infected by SARS-CoV-2.
Case report
At birth all the patient’s growth and vital parameters 
were normal and his APGAR score was  91–105. PA was 
diagnosed by NBS 5 days after birth. Molecular analysis 
of the PA genes (PCCA and PCCB), performed by next 
generation sequencing procedures (Nextera Flex tech-
nology, Illumina), identified compound heterozygo-
sity for two previously reported mutations in the PCCB 
gene, the NM_000532: c.337C > T p.(Arg113*) [17] and 
the c.1298dupA p.(Ala434Glyfs*7) [18]. Both mutations, 
each of which was present at the heterozygous status in 
one of the parents, cause premature stop codons, which 
are likely to prevent production of normal and functional 
PCCB proteins.
On his fifth day of life, due to hyperammoniemia 
(357  μmol/L, n.v < 50) and metabolic acidosis, the 
child was admitted to our hospital. Protein intake was 
stopped and intravenous glucose and lipids, l-carnitine, 
N-Carbamylglutamate, sodium benzoate and arginine 
hydrochloride were administered (Table  1). 24  h after 
hospitalization, ammonemia levels were normal and nat-
ural proteins (human milk) were reintroduced. Therapy 
with ammonia scavengers was suspended on the 9th day 
after birth (Table 1). Transfontanellar ultrasound, cardio-
logic evaluation, hearing and ophthalmological screening 
were all normal.
During the first year of life, as serum ammonia levels 
continued to be slightly above normal values, carnitine 
dosage was progressively increased and therapy with 
N-carbamylglutamate and metronidazole was introduced 
at 11 months of age. Protein intake has always been kept 
within safe limits. Clinical and biochemical parameters 
remained satisfactory during the clinical course. The 
patient’s neurodevelopmental milestones remained nor-
mal. He gained head control at 3 months of age, began to 
sit without support at 6 months and started to say some 
words at 12 months.
At the last follow-up appointment, therapy included 
l-Carnitine, N-carbamylglutamate (80  mg/kg), Vita-
min complex [Vitamin C, E, A, D3, B12 and folic acid], 
12.5  mg/kg Metronidazole in 2 doses for 15  days per 
month (Table 1).
At 1  year of age the patient was admitted to our 
hospital due to a combination of symptoms including 
vomiting, drowsiness, cold sweating, skin pallor, and 
dyspnea. His parents referred a low-grade fever in the 
previous days. A metabolic crisis was suspected. He 
was given  O2 therapy due to oxygen saturation val-
ues (as measured by pulse oximetry) being below 90% 
(Table 2). Dyspnea resolved in 2 h with  O2 therapy and 
the child remained in relatively good health and was 
Table 1 Patient’s follow-up
Before Sars-Cov-2 infection During Sars-CoV-2 infection After Sars-Cov-2 infection
Therapy l-Carnitine 750 mg × 3/die
N-carbamylglutamate (Carbaglu 80 mg/kg/
die)
Metronidazolo 125 mg in 2 doses for 15 days 
per month
Dycoflor 5 drops/die
Vitauno (DMF) 10 drops/die
l-Carnitine 750 mg × 3/die
N-carbamylglutamate (Carbaglu 100 mg/
kg/die)
Dycoflor 5 drops/die
Vitauno (DMF) 10 drops/die
l-Carnitine 750 mg × 3/die
N-carbamylglutamate (Carbaglu 80 mg/kg/
die)
Metronidazolo 125 mg in 2 doses for 15 days 
per month
Dycoflor 5 drops/die
Vitauno (DMF) 10 drops/die
Diet Milk (Nidina 1, Nestlè, 160 ml × 4/die)
Glycolipid and Vitamin supplement (BasicP, 
Milupa, Nutricia, 20 ml × 4/die)
2 salt meals/day (protein intake 13.5 g/die
Protein intake was stopped for 24 h. During 
this 24 h:
-Glucose-electrolyte infusion with a glucose 
intake of 7 mg/Kg/min
-Fat emulsion infusion (2 g/kg/day, 10% 
medium-chain triglyceride + 10% long-
chain triglyceride)
Milk (Nidina 1, Nestlè, 160 ml × 4/die)
Glycolipid and Vitamin supplement (BasicP, 
Milupa, Nutricia, 20 ml × 4/die)
2 salt meals/day (protein intake 13.5 g/die)
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able to self-feed during the crisis. Chest- Brain CT 
and ECG were normal; blood testing revealed hyper-
ammonemia and hyperglycemia (see Table  2). Chest 
echography showed a widespread increase of B lines 
with small subpleural thickenings. Glucose infusion 
and 100  mg/kg N-carbamylglutamate administration 
was followed by rapid recovery with no subsequent 
metabolic crises. Three days after admission fever 
and diarrhea appeared. Due to the occurrence of high 
fever (38.5  °C), SARS-CoV-2 infection was suspected 
and diagnosed by nasopharyngeal swab. Chest X-ray 
showed widespread, albeit mild accentuation of the 
broncho-vascular texture with a blurred aspect (Fig. 1). 
The patient’s biochemical parameters observed during 
hospitalization and Sars CoV-2 infection are presented 
in Table  2. The child was discharged 2  days after his 
fever resolved, with no further treatment. Both parents 
were infected by SARS-CoV-2 but remained asympto-
matic. Currently, the patient has normal psychomotor 
development and his family complies with therapeutic 
Table 2 Biochemical data of PA patient during Sars-CoV-2 infection
* Out of range values are italicised; n.v. normal values, ABG arterial blood gas, An infection of the urinary tract was excluded
Day of the crisis 1 2 3 5 7
10:00 a.m 11:00 a.m 2.00 p.m 5:00 p.m
Vital parameters
Sat02 (%)
95–100 90 81.1* 92.7
ABG parameters
PH (–)
N.V. 7.35–7.45 7.31 7.24* 7.35 7.42
PCO2 (mmHg)
N.V.80–100 54* 71* 44.5* 34.0*
HCO3- (mmol/L)
N.V.21–30 23.8 30.4 22.7 23.1
cLac (mg/dl)
N.V. 5–14 21* 16*
Clinical chemistry
NH4 (µmol/L)
N.V. < 50 145* 113* 113* 49 42 67*
Glycemia (mg/dl)
N.V. 60–100 162* 211* 134* 134* 107* 101* 118* 126*
Creatinine (mg/dl)
N.V.0,10–0,40 0.16 0.18 0.21 0.22
Hematology
WBC (× 10^3/µl)
N.V.3.50–14.00 5.65 6.83 8.20 4.52 10.87
PLT (× 10^3/µl)
N.V. 210–590 145* 133* 144* 188* 299
Lymphocytes (%)
N.V. 30–70 37.3 78.4* 44.7 49.2 56
Fig. 1 Patient’s chest X-ray A-P projection. Widespread mild 
accentuation of the broncho-vascular texture with blurred aspect
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recommendations. He is now 16 months of age and has 
started walking (at 15 months of age).
Discussion
SARS-CoV-2 is a single stranded RNA virus that can 
cause a severe respiratory syndrome [19]. Fever and 
cough are the most common symptoms; additional non-
specific symptoms include dyspnea, myalgia or fatigue 
and lymphopenia, while vomiting and diarrhea are less 
commonly observed [8].
Systemic reviews of COVID-19 in pediatric patients 
suggests that the clinical course of SARS CoV-2 infection 
in children is milder than in adults [12, 19, 20]. However, 
the impact of this infection on the clinical status of chil-
dren with an inborn metabolic disorder is not well known 
[16, 19].
The child we here describe, who is affected by a severe 
form of PA, was the first patient affected with SARS-
CoV-2 infection in our pediatric hospital. The infection 
was diagnosed at an early stage of the pandemic outburst 
in Italy. At that time, routine safety protocols had not yet 
been established in Italian hospitals or in the commu-
nity. The patient was tested for SARS-CoV-2 because he 
exhibited dyspnea and fever, which we knew to be sug-
gestive of COVID-19. Diagnostic investigations did not 
reveal any major abnormality at presentation or during 
the course of the infection, although mild involvement of 
the lung texture was detected by echography and by chest 
X-ray.
Current national and regional ordinances require 
patients admitted to hospital to be tested for SARS-
CoV-2 using both nasopharyngeal swabs and serological 
testing (Screen Test COVID-19, 2019-NCOV IGG/IGM 
rapid test cassette, Screen Italia srl). Since this patient 
tested positive for SARS-CoV-2, our hospital has regis-
tered 12 additional instances of metabolic decompensa-
tion in pediatric patients affected with inborn errors of 
metabolism: 6 methylmalonic acidemias, 4 PAs, 1 argini-
nosuccinate lyase deficiency and 1 glycogenosis. COVID-
19 was excluded in all of them and in their parents.
Fever is one of the most frequent causes of metabolic 
decompensation in organic acidurias [5]. Adherence to 
l-carnitine and N-carbamylglutamate treatment and 
dietary restrictions can prevent decompensation/crisis 
improving survival rate even in patients with the severe 
form of PA [4]. Appropriate management of acute meta-
bolic crises is crucial for normal intellectual development 
in PA patients [4]. Recent literature confirms that hyper-
ammonemia and metabolic decompensation have a great 
impact on patients’ outcome, and that even when diagno-
sis is a result of NBS, outcomes are not necessarily better 
[7, 21, 22].
Long-term complications affecting various organ sys-
tems are common in PA patients, and impaired physical 
development including growth retardation and psycho-
social development may further complicate the outcome 
for young/adult PA patients [4, 22]. There is still con-
troversy about the optimum natural protein intake for 
patients with PA and different therapeutic regimens are 
used by different metabolic centers [4]. During SARS-
CoV-2 infection of the here reported patient, hyperam-
monemia and glycemia promptly normalised and the 
patient was discharged a few days later, after his fever 
resolved. COVID-19 did not prompt severe metabolic 
decompensation in this patient and the used treatments 
prevented short-term complications. We suggest that for 
this patient, the protocols used to treat hyperammone-
mia at 6 days of age, strict dietary management, ongoing 
therapy and prompt intervention on the patient’s recent 
admission may have helped lessen the impact of the met-
abolic decompensation.
The continuous reassessment of COVID-19 care plans 
is crucial during the current pandemic. Sharing observa-
tions about the evolution and management of COVID-
19 infection in pediatric patients with underlying inborn 
errors of metabolism through rapid publication is vital 
[23].
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